| Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-alpha 2a: 1 year follow-up of the OSST study | |
| Han, Meifang; Jiang, Jiaji; Hou, Jinlin; Tan, Deming; Sun, Yongtao; Zhao, Mianzhi; Ning, Qin* | |
| 刊名 | Antiviral therapy
 |
| 2016 | |
| 卷号 | 21期号:4页码:337-344 |
| ISSN号 | 1359-6535 |
| DOI | 10.3851/IMP3019 |
| URL标识 | 查看原文 |
| WOS记录号 | WOS:000389746700007 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3335794 |
| 专题 | 中南大学 |
| 作者单位 | 1.[Han, Meifang 2.Ning, Qin] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China. |
| 推荐引用方式 GB/T 7714 | Han, Meifang,Jiang, Jiaji,Hou, Jinlin,et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-alpha 2a: 1 year follow-up of the OSST study[J]. Antiviral therapy,2016,21(4):337-344. |
| APA | Han, Meifang.,Jiang, Jiaji.,Hou, Jinlin.,Tan, Deming.,Sun, Yongtao.,...&Ning, Qin*.(2016).Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-alpha 2a: 1 year follow-up of the OSST study.Antiviral therapy,21(4),337-344. |
| MLA | Han, Meifang,et al."Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-alpha 2a: 1 year follow-up of the OSST study".Antiviral therapy 21.4(2016):337-344. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论